LATISSE® (bimatoprost ophthalmic solution) 0.03%, approved by the U.S. Food and Drug Administration (FDA) in 2008, is a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. LATISSE® is the first and only FDA-approved, science-based treatment to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.
Available only through a doctor, LATISSE® is a once-daily prescription treatment applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. LATISSE® users can expect to experience longer, fuller and darker eyelashes in as little as eight weeks, with full results in 16 weeks. To maintain effect, continued treatment with LATISSE® is required. If use of LATISSE® is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of weeks to months (average eyelash hair cycle).